Realisation off established targets at patients with diabetes type 2 at primary care setting.
Recruiting
- Conditions
- diabetes type II
- Registration Number
- NL-OMON25745
- Lead Sponsor
- Aventis Pharma(primair)GSKBMSMerck
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 500
Inclusion Criteria
1. Patients with type 2 diabetes;
2. Signed informed consent.
Exclusion Criteria
1. Age < 18 years;
2. QALY < 5 Years;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The total amount of targets reached with treatment with Rosiglitazone compared with treatment with no Rosiglitazone.
- Secondary Outcome Measures
Name Time Method The outcome of glitazone to the recent discovered riskfactors of diabetic patients.